Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Reactions
Skin
Adverse effects (sic) (53%)
(2000): John W+, Cancer 88(8), 1807 (53%)
(2000): Miller KD+, Ann Oncol 11(1), 101
Allergic reactions (sic)
Desquamation (22%)
Peripheral edema
Photo-recall
(2006): Barlesi F+, Lung Cancer 54(3), 423
Pressure necrosis
Pruritus
Purpura
Rash (sic) (42%)
(2003): Martin M+, Ann Oncol 14(8), 1246
(2001): Miles DW+, Eur J Cancer 37(11), 1366 (42%)
(1999): Cripps C+, Ann Oncol 10(10), 1175
Vasculitis
(2006): Lopes G+, Lung Cancer 51(2), 247 (urticaral)
Mucosal
Aphthous stomatitis
Gingivitis
Mucositis (5–17%)
(2004): Calvert AH+, Oncology (Williston Park) 18(13 Suppl
8), 13
(2001): Miles DW+, Eur J Cancer 37(11), 1366 (5%)
(2001): Pivot X+, Br J Cancer 85(5), 649 (17.1%)
Stomatitis (5%)
(2006): Sweeney CJ+, J Clin Oncol 24(21), 3451
(2006): von der Masse H+, Ann Oncol 17(10), 1533 (with
gemcitabine)
(2003): Martin M+, Ann Oncol 14(8), 1246 (5%)
(1999): Cripps C+, Ann Oncol 10(10), 1175
Eyes
Eyelid edema
(2006): Kurata T+, Lung Cancer 54(2), 241
Other
Abdominal pain
(1999): Cripps C+, Ann Oncol 10(10), 1175
Chills
Cough
Death
(1999): Cripps C+, Ann Oncol 10(10), 1175
Fever
(1999): Cripps C+, Ann Oncol 10(10), 1175
Hepatotoxicity
(2006): Brandes JC+, Cancer Invest 24(3), 283
Hypersensitivity (2%)
Infections
(2004): Calvert AH+, Oncology (Williston Park) 18(13 Suppl
8), 13
(2001): Miles DW+, Eur J Cancer 37(11), 1366
Pain
Rhabdomyolysis
(2006): Ceribelli A+, Lancet Oncol 7(4), 353
PEMIROLAST
Trade names: Alamast (Johnson & Johnson); Alegysal
Indications: Pruritus of allergic conjunctivitis
Category: Mast cell stabilizer
Half-life: 4.5 hours
Skin
Allergic reactions (sic)
Eyes
Ocular burning
Ocular stinging (